Francesco Leone, Salvatore Artale, Donatella Marino, Celeste Cagnazzo, Stefano Cascinu, Carmine Pinto, Giuseppe Fornarini, Marco Tampellini, Francesca Di Fabio, Andrea Sartore-Bianchi, Luciano De Carlis, Raffaele Pugliese, Lorenzo Capussotti, Luisa Gioeni, Salvatore Siena and Massimo Aglietta Panitumumab in combination with infusional oxaliplatin and oral capecitabine for conversion therapy in patients with colon cancer and advanced liver metastases Cancer 119
Article first published online: 18 JUL 2013 | DOI: 10.1002/cncr.28223
Primary chemotherapy is the standard treatment for patients with colorectal cancer with liver metastases. Patients with wild-type KRAS colon cancer with exclusive and extensive liver involvement were found to have high response (65%) and resectability (43%) rates after conversion therapy with panitumumab and the combination of capecitabine plus oxaliplatin (XELOX).
Complete the form below and we will send an e-mail message containing a link to the selected article on your behalf
Required = Required Field
Choose captcha format: Image or Audio. Click here if you need help.